DL
Daniel A. Laheru
Elite in Pancreatic Cancer
Check Dr. Daniel A. Laheru's experience treating your condition:
About Dr. Daniel A. Laheru

Daniel Laheru is an Oncologist in Baltimore, Maryland. Laheru has been practicing medicine for over 28 years and is rated as an Elite expert by MediFind in the treatment of Pancreatic Cancer. He is also highly rated in 17 other conditions, according to our data. His top areas of expertise are Pancreatic Cancer, Familial Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Pancreatic Adenoma, and Gamma Knife Radiosurgery. He is licensed to treat patients in Maryland. Laheru is currently accepting new patients.

His clinical research consists of co-authoring 159 peer reviewed articles and participating in 18 clinical trials in the past 15 years. In particular, he has co-authored 127 articles and participated in 14 clinical trials in the study of Pancreatic Cancer.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Daniel A. Laheru it is best to call his office and ask if your insurance is accepted.

Accepts Medicare
Locations
600 N Wolfe St, Baltimore, MD 21287
Background & Education
Graduate Institution
Baylor College Of Medicine, 1995
Specialties
Oncology
Licenses
Internal Medicine in MD
Hospital Affiliations
The Johns Hopkins Hospital
Howard County General Hospital
Johns Hopkins Bayview Medical Center
Sibley Memorial Hospital
Languages Spoken
English
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


17 Clinical Trials

Precision Promise Platform Trial for Metastatic Pancreatic Cancer
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Neoantigen DNA Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy
A Safety and Efficacy Trial of Vaccine Boosting With Lethally Irradiated Allogeneic Pancreatic Tumor Cells Transfected With the GM-CSF Gene for the Treatment of Pancreatic Adenocarcinoma
A Randomized Phase 2 Study of Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy
Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)
A Phase II Clinical Trial of GVAX Pancreas Vaccine (With Cyclophosphamide) in Combination With Nivolumab and Stereotactic Body Radiation Therapy (SBRT) Followed by Definitive Resection for Patients With Borderline Resectable Pancreatic Adenocarcinoma
View 14 Less Clinical Trials -

Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
Elite
Elite
Elite